Positive new Phase III data on Roche's Vabysmo in RVO

10 February 2023

With its Vabysmo (faricimab) already approved in more than 50 markets including the USA and Europe for the treatment of wet, or neovascular, age-related macular degeneration (AMD), Swiss pharma giant Roche (ROG: SIX) is now touting the benefits of the drug in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO).

Roche today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo in BRVO and CRVO) at 24 weeks.

The studies showed that treatment with Vabysmo resulted in early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains compared to treatment with aflibercept, Bayer’s (BAYN: DE) blockbuster drug Eylea.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK